

行政院國家科學委員會專題研究計畫 成果報告

天然資源中新先導藥物之探索(Ⅱ~Ⅳ)--台灣產海綿、珊瑚及濱海生物活性成分研發(子計畫七)
研究成果報告(精簡版)

計畫類別：整合型
計畫編號：NSC 95-2323-B-002-018-
執行期間：95年08月01日至96年07月31日
執行單位：國立臺灣大學醫學院藥學系暨研究所

計畫主持人：沈雅敬

計畫參與人員：博士班研究生-兼任助理：鄭源斌、羅光良
碩士班研究生-兼任助理：林俊州、吳盈儒
博士後研究：卡力
輔仁大學教授：郭育綺

處理方式：本計畫可公開查詢

中華民國 96 年 10 月 24 日

國科會專題研究計畫成果報告撰寫格式

一、說明

國科會基於學術公開之立場，鼓勵一般專題研究計畫主持人發表其研究成果，但主持人對於研究成果之內容應負完全責任。計畫內容及研究成果如涉及專利或其他智慧財產權、違異現行醫藥衛生規範、影響公序良俗或政治社會安定等顧慮者，應事先通知國科會不宜將所繳交之成果報告蒐錄於學門成果報告彙編或公開查詢，以免造成無謂之困擾。另外，各學門在製作成果報告彙編時，將直接使用主持人提供的成果報告，因此主持人在繳交報告之前，應對內容詳細校對，以確定其正確性。

本格式說明僅為統一成果報告之格式，以供撰寫之參考，並非限制研究成果之呈現方式。精簡報告之篇幅（不含封面之頁數）以 4 至 10 頁為原則，完整報告之篇幅則不限制頁數。

成果報告繳交之期限及種類（精簡報告、完整報告或期中報告等），應依本會補助專題研究計畫作業要點及專題研究計畫經費核定清單之規定辦理。

二、內容格式：依序為封面、中英文摘要、目錄（精簡報告得省略）、報告內容、參考文獻、計畫成果自評、可供推廣之研發成果資料表、附錄。

(一)報告封面：請至本會網站(<http://www.nsc.gov.tw>)下載製作(格式如附件一)。

(二)中、英文摘要及關鍵詞(keywords)。

(三)報告內容：請包括前言、研究目的、文獻探討、研究方法、結果與討論（含結論與建議）…等。若該計畫已有論文發表者，可以 A4 紙影印，作為成果報告內容或附錄，並請註明發表刊物名稱、卷期及出版日期。若有與執行本計畫相關之著作、專利、技術報告、或學生畢業論文等，請在參考文獻內註明之，俾可供進一步查考。

(四)頁碼編寫：請對摘要及目錄部分用羅馬字 I、II、III……標在每頁下方中央；報告內容至附錄部分請以阿拉伯數字 1.2.3……順序標在每頁下方中央。

(五)附表及附圖可列在文中或參考文獻之後，各表、圖請說明內容。

(六)計畫成果自評部份，請就研究內容與原計畫相符程度、達成預期目標情況、研究成果之學術或應用價值、是否適合在學術期刊發表或申請專利、主要發現或其他有關價值等，作一綜合評估。

(七)可供推廣之研發成果資料表：凡研究性質屬**應用研究及技術發展**之計畫，請依本會提供之表格（如附件二），每項研發成果填寫一份。

三、計畫中獲補助國外或大陸地區差旅費、出席國際學術會議差旅費或國際合作研究計畫差旅費者，須依規定撰寫心得報告，以附件方式併同成果報告繳交，並請於成果報告封面註記。

四、打字編印注意事項

1. 用紙

使用 A4 紙，即長 29.7 公分，寬 21 公分。

2. 格式

中文打字規格為每行繕打(行間不另留間距)，英文打字規格為 Single Space。

3. 字體

報告之正文以中英文撰寫均可。在字體之使用方面，英文使用 Times New Roman Font，中文使用標楷體，字體大小請以 12 號為主。

行政院國家科學委員會補助專題研究計畫 成果報告
 期中進度報告

台灣產海綿, 珊瑚及濱海生物活性成分研究 (96 年度成果報告)

計畫類別： 個別型計畫 整合型計畫

計畫編號：NSC 95-2323-B-002-018

執行期間：95 年 8 月 1 日至 96 年 7 月 31 日

計畫主持人：沈雅敬

共同主持人：

計畫參與人員：鄭源斌、羅光良、林俊州、吳盈儒、郭育綺、卡力

成果報告類型(依經費核定清單規定繳交)： 精簡報告 完整報告

本成果報告包括以下應繳交之附件：

- 赴國外出差或研習心得報告一份
- 赴大陸地區出差或研習心得報告一份
- 出席國際學術會議心得報告及發表之論文各一份
- 國際合作研究計畫國外研究報告書一份

處理方式：除產學合作研究計畫、提升產業技術及人才培育研究計畫、
列管計畫及下列情形者外，得立即公開查詢

涉及專利或其他智慧財產權， 一年 二年後可公開查詢

執行單位：台大藥學系

中 華 民 國 96 年 10 月 24 日

中文摘要:

. 對叢羽珊瑚 *Cespitularia hypotentaculata* 成份研究, 發現 8 個新 Verticillene 雙帖類化合物, 命名為 cespiphytins E-L, 對免疫調控作用進行測試發現, 其中 cespiphytin K 對 PHA 所引起的 PBMC 細胞增生有促進作用, 而 cespiphytin L 則有抑制作用。成果投稿至下列雜誌。

關鍵詞: *Cespitularia hypotentaculata* 叢羽軟珊瑚; verticillene 雙帖類化合物; cespiphytins; 免疫調節作用。

Ya-Ching Shen, Ying-Ru Wu, Jyun-Jhou Lin, Yuh-Chi Kuo and Ashraf Taha Khalil, 2007,
“Eight New Diterpenoids from Soft Coral *Cespitularia hypotentaculata*”, *Tetrahedron*, **63**,
10914-10920. (SCI)

Abstract (英文摘要)

Chemical investigation of the soft coral *Cespitularia hypotentaculata* resulted in the isolation of eight new diterpenes, cespiphytins E-L (**1-8**). The new metabolites comprised six verticillene-type diterpenes and one cespitularane derivative, and one derivative with fourteen-membered lactone ring. The structures were determined through detailed spectroscopic analyses, especially high resolution ESI-MS and 2D NMR techniques. The relative stereochemistry was deduced from NOESY spectrum and application of Mosher's ester technique. Immunomodulatory and antiviral activities of **1-8** were tested and evaluated. The biogenetic pathways for **1-8** were also proposed.

Keyword: *Cespitularia hypotentaculata*; verticillene diterpenes; cespiphytins;
Immunomodulatory activity

可供推廣之研發成果資料表

 可申請專利 可技術移轉

日期：__年__月__日

國科會補助計畫	計畫名稱： 計畫主持人： 計畫編號： 學門領域：
技術/創作名稱	
發明人/創作人	
技術說明	中文： (100~500 字)
	英文：
可利用之產業 及 可開發之產品	
技術特點	
推廣及運用的價值	

※ 1. 每項研發成果請填寫一式二份，一份隨成果報告送繳本會，一份送 貴單位研發成果推廣單位（如技術移轉中心）。

※ 2. 本項研發成果若尚未申請專利，請勿揭露可申請專利之主要內容。

※ 3. 本表若不敷使用，請自行影印使用。

1. Introduction

The soft coral *Cespitularia* (Xeniidae) live in colonies with polyps occurring on the branches with white, cream, blue, brown, or iridescent-green surface.¹ This genus elaborate varied diterpenoids of cembrane, neodolabellane, cespitularane and verticillane skeleton,²⁻⁷ some of these compounds demonstrated cytotoxic activities.⁷⁻⁹ The verticillene skeleton is basically bicyclic (9.3.1) diterpenes with some resemblance to taxane diterpenes isolated from various species of terrestrial *Taxus* trees, especially the β -*gem*-dimethyl attached to the cyclohexane group.¹⁰ Some nor-verticillene have been also isolated, together with cespitularane with 14-membered lactone ring between C-10 and C-12.^{7,11} Chemical investigation of the *C. hypotentaculata* Roxas resulted in the isolation of eight new diterpenes, cespiphytins E-L (**1-8**). The new metabolites comprised six verticillene-type diterpenes **2-5**, **7-8**, one cespitularane derivative **6**, and one derivative with fourteen-membered lactone ring **1**. The biological activities of compounds **1-8** were tested against HSV-1 virus and evaluated with peripheral blood mononuclear cell (PBMC) proliferation induced by phytohemagglutinin (PHA).

2. Results and discussion

2.1. Structure of compound 1

The molecular formula of cespiphytin E (**1**), $[\alpha]_D^{26} +52.1^\circ$ (EtOAc), was established as C₁₉H₂₈O₄ from HR-ESIMS. The UV and IR spectra revealed α,β -unsaturated ester, hydroxyl and carbonyl groups. The ¹³C NMR data unveiled an exomethylene, trisubstituted double bond, a carbonyl (δ_C 210.6), a conjugated ester carbonyl (δ_C 166.5), *gem*-methyls (δ_C 28.1, 22.9), and a vinyl methyl (δ_C 20.3) suggesting a bicyclic [6.3.1] nor-diterpene. The ¹H NMR spectrum revealed an oxymethine proton at δ_H 3.67 (H-6) by virtue of HMBC correlation to C-4, and COSY correlations to two CH_2 (H-5 and H-7). HMBC correlations between H-6/C-8; Me-19/C-7, C-9; between H-9/C-7, and between H-9/C-10 located unsaturation at C-8 and the ester carbonyl at C-10. The *gem*-protons (H-16 and H-17) displayed correlations to C-1 and the carbonyl (C-11),

while correlation of H-12/C-10, C-13, C-11 allowed assigning the latter carbonyl to C-11 in the cyclohexanone ring that was attached at C-12 to the conjugated carbonyl forming 14-membered lactone ring. The NOESY spectrum of **1** revealed correlations between Me-19/H-6, H-9; H-9/H_α-7; H_β-3/Me-16, Me-17; Me-16/H-1, H-12, Me-17 indicating the α-configuration of H-6 and the β-configuration of H-12. The NOESY correlation between M-19/H-9 was in accordance with Z-geometry of the 8,9-double bond. These data were closely similar to those reported for cespitulactone A but with different position and arrangement of the double bond.⁸

2.2. Structure of compound 2

The HR-ESI-MS of **2**, [α] -25.1° (acetone), revealed that cespiphytin F had a molecular formula C₂₀H₂₆O₄Na. The IR spectrum displayed absorption band diagnostic of lactone (1752 cm⁻¹) and conjugated carbonyl (1682 cm⁻¹) groups. The ¹³C NMR data showed two carbonyls (δ_C 199.0, 170.1), exomethylene double bond (δ_C 143.7, 115.9), a trisubstituted double bond (δ_C 129.8, 150.3), and a double bond adjacent to a carbonyl, that implied a tricyclic compound. The ¹H NMR spectrum (Table 1) displayed an olefinic proton singlet (δ_H 6.40), two exomethylene singlets (δ_H 4.94 and 4.85), and three methyl singlets. HMBC revealed correlations of H-19/C-7, C-8, C-9, and correlations of H-7/C-8, C-6. Moreover, the two geminal protons (H-5) correlated to C-18, and the carbonyl (C-6). Each of the methyl singlets correlated with one another and with C-15, C-1, and C-11. COSY connectivities between CH₂-3/H₂-2/H-1/H₂-14/H₂-13, and HMBC correlations of H-1/C-11, C-13, C-15 suggested that the two *gem*-methyls are attached to a quaternary carbon in a cyclohexene ring. The presence of γ -hydroxy- α,β -unsaturated- γ -lactone was evident from conjugated carbonyl at δ_C 170.1 (C-20), 129.1 (C-12), 167.2 (C-11), and 108.2 (C-10). The aforementioned data were in accordance with those of cespitularin D, a 1*S*-verticillene-type diterpene previously isolated from *C. hypotentaculata*, in which a hydroxyl group at C-6 was replaced by a carbonyl in **2**.⁷ The relative stereochemistry of **2** was determined on basis of biogenetic consideration and analysis of NOESY spectrum. The correlations between H_β-13/H-16, H-1; H-17/H-1, H_β-14; and H-7/H_β-5, H-17 indicated that H-1, H-7, Me-16, and Me-17 were on β-face of the molecule. Additionally,

NOESY correlation between Me-19/H_α-9 suggested that Me-19 was on the α-side of the molecule, while absence of Me-19/H-7 favored the *E*-geometry of the 7,8-double bond.

2.3. Structure of compound 3

Compound **3**, [α] -15.6° (*c* 0.6, acetone), had a molecular formula C₂₀H₃₀O₅ as deduced from HR-ESIMS. The IR spectrum of **3** unveiled the absence of carbonyl group. The NMR data of **3** was similar to those of **5** with the exception of absence of signals attributable to an acetyl group. The oxymethine proton at δ_H 4.49, having COSY correlation with H-5, H-7, and HMBC correlation to C-7, C-5, was assigned to H-6. A second oxymethine resonating at δ_H 4.70 was assigned to H-20 as a result of its HMBC correlations to C-12 (δ_C 78.2), C-11 (δ_C 74.3) as well as the acetal carbon at δ_C 94.7 (C-10). The NOESY correlation between H-6/H_α-5, H-19; H-19/H_α-9; H_β-9/H-7, H-16, H-17; H-1/H-16, H-17, H-20 revealed the α-orientation of H-6 and β-orientation of H-20.

2.4. Structure of compound 4

The molecular formula C₂₃H₃₂O₆ was assigned to **4** based on its HR-ESI-MS (*m/z* 427.2096, [M+Na]⁺). The NMR data (Tables 1 and 2) were in accordance with a verticillene-type diterpene ester. The NMR spectra disclosed signals at δ_C 164.8 (conjugated carbonyl), δ_C 127.8, δ_C 132.5, as well as characteristic *cis*- and *trans*-couplings at δ_H 6.51 (d, *J* = 15.7 Hz), 5.93 (d, *J* = 10.0 Hz), and 6.18 (m), with HMBC correlations between these protons and the carbonyl, thereby proving the presence of acrylate ester. Other ¹H- and ¹³C NMR signals as well as COSY of **4** were very similar to those of **3**. The oxymethine at δ_H 5.86 (s, H-20) correlated in HMQC spectrum with CH at δ_C 96.6, and in HMBC with the ester carbonyl (C-21), C-10, and CH₂-13. The eight degrees of unsaturation required additional ring that was deduced to be an epoxy ring involving two oxyquaternary carbons at δ_C 78.8 and δ_C 75.1. This was proved by HMBC correlations of H-16, H-17 to C-11 and of H-20 to C-11 and C-12. The relative configuration of **4** was established on the basis of correlations with **3** and NOESY experiments. NOESY correlations between

H-1/H_β-13, H-16, H_β-14, H-17, H-20; and H-7/H_β-5, H-17 indicated that H-1, H-7, Me-16, Me-17, and H-20 were on β-face (Fig. 1). NOESY correlation between Me-19/H_α-9; H-6/H_α-5, H-19 suggested that H-6 was on the α-oriented.

2.5. Structure of compound 5

Compound **5**, [α] -15.6° (acetone), had a molecular formula C₂₂H₃₂O₆ as derived from HR-ESI-MS at m/z 415.2098 ([M+Na]⁺). The UV bands and IR adsorptions were similar to those of **3** and **4**, suggestion a close analogue. The ¹H- and ¹³C NMR data of **5** were also similar to those of **4** with the exception of the absence of signals assignable to the acrylate ester and presence of signals of acetate ester at δ_C 170.1(s), δ_C 20.9 (q) and δ_H 2.11(s). The oxymethine at δ_H 5.62 (s, H-20) had HMBC correlations to the acetate carbonyl (δ_C 170.1) as well as C-13 validating the attachment of acetoxy group to C-20. HMBC and NOESY correlations were identical to those of **4**.

2.6. Structure of compound 6

Compound **6**, [α] +57.6° (CH₂Cl₂) possessed a molecular formula C₂₄H₃₂O₅ as established from HR-ESI-MS. The spectroscopic data of **6** clearly indicated the presence of two acetate moieties (δ_H 2.01, 2.12). One was attached to C-6, as indicated by correlations of H-6 to C-4 (δ_C 144.7), ester carbonyl, and C-8 (δ_C 134.9). The ¹³C NMR spectrum revealed the presence of α,β -unsaturated ketone (δ_C 202.6, 147.9 and 165.7), which was verified by COSY and HMBC. COSY correlation of H-20/H-9, and HMBC correlations of H-20/C-8, and H-20/acetate carbonyl (δ_C 170.5) implied acetoxy group at C-20. Furthermore, the HMBC correlations between H-9/C-7, C-8, C-10, C-11, C-12, C-20; H-20/C-8, C-11, C-12; H-13/C-12; H-16/C-1, C-11, allowed to assign α,β -unsaturated- γ -acetyloxy-cyclopentenone. These data were analogous those of cespitularin F previously isolated from *C. taeniata* with an extra-acetyl group at C-6.⁸ NOESY correlations between H-1/H-9, H-17; H-9/H-20; H-7/H-17 suggested that H-1, H-9, H-20, H-16, H-17 were on the β-face of the molecule and H-6 was α-oriented (Fig. 2). Absence

of correlation between H-7 and H-19 was in agreement with *E*-arrangement of the 7,8-double bond.

2.7. Structure of compound 7

Cespihypotin K (**7**), $[\alpha] -5.8^\circ$ (acetone), was analyzed for molecular formula $C_{20}H_{32}O_2$ from its HRESIMS. The COSY spectrum exhibited connectivities between H-5/H-6/H-7 and between H-9/H-10. In addition to exomethylene double bond (δ_C 109.6, 151.2), a tetra-substituted double bond was detected at δ_C 133.9 (C-12) and 140.2 (C-11) by HMBC (C-11/Me-16, Me-17, Me-20 and Me-20/C-11, C-12, C-13). An oxymethine carbon (δ_C 67.1, C-10) was directly bonded to H-10 and the latter correlated to C-11 and C-12 and C-15 (δ_C 37.1). The signals of δ_C 65.2, δ_C 59.5, and δ_H 2.82 were diagnostic of epoxy ring that was placed at 7,8-position based on HMBC correlations between H-5/C-7; H-7/C-6; H-19/C-7, C-8, C-9; and H-10/C-8. The NOESY correlations between H-19/H-7, H-10; H-17/H-1, H-10, H-16 were in agreement with β -orientation of H-7, H-10, Me-19 as well as the α -form of the epoxy ring.

2.8. Structure of compound 8

Compound **8**, $[\alpha] -121.8^\circ$ (CH_2Cl_2), proved to have molecular formula $C_{22}H_{32}O_4$ by HR-ESI-MS. The 1H - and ^{13}C NMR spectroscopic data (Tables 1 and 2) indicated the same sequence from C-1 to C-9 as those of **5**. The ^{13}C NMR disclosed two carbonyls at δ_C 207.4 (C-10) and 166.9 (C-20). The H-9 (δ_H 3.50 and 3.13) had HMBC correlations to C-7 (δ_H 5.54), and C-10. Each of Me-16, Me-17, and H₂-13 exhibited correlation to C-11. An ethyl moiety was detected at δ_C 61.2 and δ_C 14.1. It was concluded that an ethoxy group was attached to C-20 that was confirmed through HMBC correlation of H-21 (δ_H 4.17) and C-20. The NOESY correlations between H $_{\alpha}$ -5/H-6, H-18; H-19/H-6, H $_{\alpha}$ -9; H $_{\beta}$ -9/ H-7, H-16, H-17; H-16/H-1, H-17 that suggested that H-6, H-18, Me-19 were α -face of the molecule, while H-1, H-7, Me-16, Me-17 had the β -orientation. The absolute configuration at C-6 was further confirmed by modified Mosher's method.¹³ The difference values for right-sided protons H-7, H-9, H-19 were (+0.16), (+0.06), and (+0.01)

respectively, while values for left-sided protons were H-5 (-0.11) and H-18 (-0.05). The results demonstrated the (*S*)-configuration at C-6.

Plausible biogenetic pathways of new compounds were proposed as shown in Scheme 1 based on recently published diterpenoids.^{8,11,12} Cespitularin C, derived from GGDP via 1*S*-verticillene might be the precursor of all the isolated diterpenes. Compounds **2-5** may be transformed from cespitularin D. Compound **6** might be transformed from intermediate **a**, an important analogue of **8**. The occurrence of the latter is of significance from a biogenetic point of view.

The isolated diterpenes **1-8** were tested *in vitro* against HSV-1 virus. As indicated in Table 3, they exhibited weak activity as compared with acyclovir. A preliminary study on resting cells and cells activated with PHA were tested with compounds **1-8** at 100 μ M. The inhibition or enhancement of cell proliferation were determined by tritiated thymidine uptake. As indicated in Table 4, compound **7** showed significant enhancement of cell proliferation, while compound **8** exhibited inhibition on peripheral blood mononuclear cells (PBMC) proliferation induced by phytohemagglutinin (PHA).

3. Experimental

3.1. General

Optical rotations were recorded on a JASCO DIP-1000 polarimeter. IR spectra were measured on Hitachi U-3210 spectrophotometers. The ¹H, ¹³C NMR, COSY, HMQC, HMBC, and NOESY spectra were recorded on a Bruker FT-300 spectrometer using TMS as internal standard. The chemical shifts are given in δ (ppm) and coupling constants in Hz. Low resolution EIMS and high resolution ESI-MS were operated on JEOL JMS-HX 110 mass spectrometer. Silica gel 60 (Merck) was used for column chromatography (CC), and pre-coated silica gel plates (Merck, Kieselgel 60 F-254, 1mm) were used for preparative TLC. Sephadex LH-20 (Amersham Pharmacia Biotech AB, Uppsala, Sweden) was used for separation.

3.2. Animal Material

The soft coral *Cespitularia hypotentaculata* Roxas (Xeniidae) was collected at Green island, off the eastern coast of Taiwan, in December 2004, by scuba diving at a depth of 15 m. The fresh coral was immediately frozen after collection and kept at -20° C until processed. A voucher specimen (NTUO-5) was deposited in School of Pharmacy, College of Medicine, National Taiwan University, Taiwan.

3.3. Extraction and Isolation

The soft coral (wet, 8 kg) was extracted with CH₂Cl₂/MeOH (1:1, 3X10 L) at r.t. and the extract was concentrated under vacuum. The crude extract (20 g) was partitioned between EtOAc and H₂O (1:1). The EtOAc-soluble portion was subjected to flash column (silica gel, *n*-hexane/EtOAc 100:0→ 0:100). The fraction eluted with *n*-hexane/EtOAc (4:1) was separated on Sephadex LH-20 using CH₂Cl₂/MeOH (1:1) to furnish five fractions (*S*₁-*S*₅). This was followed fractionation of *S*₃ by silica gel column (70-230 mesh) eluting gradiently with *n*-hexane/EtOAc (15:1→0:1) (*F*₁-*F*₁₆). Fraction *F*₈ eluted with *n*-hexane/EtOAc (8:1) was chromatographed on silica gel column (230-400 mesh) using a gradient of *n*-hexane/CH₂Cl₂/MeOH. Fraction eluted with the previous solvent (ratio, 20:20:1) was further subjected to separation on NP-HPLC using *n*-hexane/acetone (5:1) to yield **2** (6 mg), and **7** (4 mg), while fraction eluted with ratio (18:18:1) was separated on NP-HPLC using *n*-hexane/acetone (9:2) to yield **4** (6 mg) and **1** (14 mg). Fraction *F*₉ eluted with *n*-hexane/EtOAc (7:1) was chromatographed on silica gel column using a gradient of *n*-hexane/acetone (4:1) followed by NP-HPLC using *n*-hexane/CH₂Cl₂/MeOH (12:12:1) to give **5** (9 mg). Fraction *F*₁₀ eluted with *n*-hexane/EtOAc (6:1) was chromatographed on RP-HPLC using MeOH/H₂O/MeCN (70:25:5) to produce **3** (7 mg), **6** (5 mg) and **8** (16 mg).

3.3.1. Cespiphyotin E (1). $[\alpha]_D^{26} = +52.1^\circ$ (*c* 0.25, EtOAc); UV λ_{\max} (log ϵ) 219 (3.8) nm; IR (CH₂Cl₂) ν_{\max} 3448 (OH), 1737 (C=O), 1662 (double bond), 1256, 898 cm⁻¹; ¹H NMR (300 MHz,

CDCl₃) Table 1; ¹³C NMR (75 MHz, CDCl₃) Table 2; HRESIMS *m/z* 343.1882 [M+Na]⁺ (calcd for C₁₉H₂₈O₄Na, 343.1885).

3.3.2. Cespiphytin F (2). $[\alpha]_D^{26} = -25.1^\circ$ (*c* 0.25, acetone); UV λ_{\max} (log ϵ) 226 (4.0) nm; IR (CH₂Cl₂) ν_{\max} 3417 (OH), 2926 (C-H), 1752 (lactone), 1682 (conj. C=O), 1614 (double bond), 1267, 910, 828, 735 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) Table 1; ¹³C NMR (75 MHz, CDCl₃) Table 2; HRESIMS *m/z* 353.1731 [M+Na]⁺ (calcd for C₂₀H₂₆O₄Na, 353.1729).

3.3.3. Cespiphytin G (3). $[\alpha]_D^{26} = -15.6^\circ$ (*c* 0.6, acetone); UV λ_{\max} (log ϵ) 208 (3.2) nm; IR (CH₂Cl₂) ν_{\max} 3422 (OH), 2931, 1645 (double bond), 998 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) and ¹³C NMR (75 MHz, CDCl₃) Tables 1 and 2; HRESIMS *m/z* 373.1991 [M+Na]⁺ (calcd for C₂₀H₃₀O₅Na, 373.1998);

3.3.4. Cespiphytin H (4). $[\alpha]_D^{26} = -2.2^\circ$ (*c* 0.25, acetone); UV λ_{\max} (log ϵ) 215 (3.7) nm; IR (CH₂Cl₂) ν_{\max} 3447 (OH), 2925, 1711 (conj. ester), 1636 (double bond), 1266, 983, 886 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) and ¹³C NMR (75 MHz, CDCl₃) Tables 1 and 2; HRESIMS *m/z* 427.2096 [M+Na]⁺ (calcd for C₂₃H₃₂O₆Na, 427.2093).

3.3.5. Cespiphytin I (5). $[\alpha]_D^{26} = -15.6^\circ$ (*c* 0.8, acetone); UV λ_{\max} (log ϵ) 206 (3.2) nm; IR (CH₂Cl₂) ν_{\max} 3421 (OH), 2929, 1747 (ester C=O), 1638 (double bond), 1219, 948, 892, 855 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) and ¹³C NMR (75 MHz, CDCl₃) Tables 1 and 2; HRESIMS *m/z* 415.2098 [M+Na]⁺ (calcd for C₂₂H₃₂O₆Na, 415.2096).

3.3.6. Cespiphytin J (6). $[\alpha]_D^{26} = +57.6^\circ$ (*c* 0.25, CH₂Cl₂); UV λ_{\max} (log ϵ) 232 (4.1) nm; IR (CH₂Cl₂) ν_{\max} 2928, 1736 (ester), 1695 (conj. C=O), 1641 (double bond), 1232 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) and ¹³C NMR (75 MHz, CDCl₃) Tables 1 and 2; HRESIMS *m/z* 423.2147 [M+Na]⁺ (calcd for C₂₄H₃₂O₅Na, 423.2150).

3.3.7. Cespiphytin K (7). $[\alpha]_D^{26} = -5.8^\circ$ (*c* 0.25, acetone); UV λ_{\max} (log ϵ) 207 (4.5) nm; IR

(CH₂Cl₂) ν_{\max} 3420 (OH), 2928, 1645 (double bond), 1265 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) and ¹³C NMR (75 MHz, CDCl₃) Tables 1 and 2; HRESIMS m/z 327.2300 [M+Na]⁺ (calcd for C₂₀H₃₂O₂Na, 327.2303).

3.3.8. Cespipotin L (8). $[\alpha]_D^{26} = -121.8^\circ$ (*c* 0.25, CH₂Cl₂); UV λ_{\max} (log ϵ) 226 (4.2) nm; IR (CH₂Cl₂) ν_{\max} 3435 (OH), 2932 (C-H), 1715 (ester), 1684 (conj. C=O), 1633 (double bond), 1246 (C-O) cm⁻¹; ¹H NMR (300 MHz, CDCl₃) and ¹³C NMR (75 MHz, CDCl₃) Tables 1 and 2; HRESIMS m/z 383.2198 [M+Na]⁺ (calcd for C₂₂H₃₂O₄Na, 383.2196). Preparation of (R)- and (S)-MTPA esters of (8). S-(+)- or R-(-)-MTPA chloride (1.5 mg) was added to a solution of (8) (3 mg in 0.5 ml pyridine) and the solution was allowed to stand at room temperature for 7 h. After purification using preparative TLC, each ester (1.8 mg, 90% yield) was submitted to ¹H NMR analysis and $\Delta\delta = \delta_S - \delta_R$ was calculated.

3.4.1. Cell culture and viruses

Vero cells were cultured in minimal essential medium (MEM; GIBCO, Grand Island, NY) supplement with 10% fetal calf serum (FCS; Hyclone, Logan, UT), 100 U/ml penicillin, and 100 µg/ml streptomycin and incubated at 37 °C in a 5% CO₂ incubator. To prepare HSV-1 (KOS strain, VR-1493, ATCC) stocks, Vero cells were infected by HSV-1 at a multiplicity of infection of 3 plaque forming units (PFU)/cell and harvested at 24 hr post-infection and centrifuged at 1500 x *g* (Centrifuge 5810 R, Eppendorf) at 4 °C for 20 min. The supernatant was collected and stored at -70 °C for use.

3.4.2. Plaque reduction assay

The assay followed procedures described previously.¹⁴ Acyclovir was used as a positive control. Vero cells (3.5 x 10⁵/dish) were incubated with 100 PFU of HSV-1 and various compounds (10 µM) or acyclovir (2.5 µM) were added to the cells. The viruses were adsorbed for 1 hr at 37 °C and 1 % methylcellulose was added to each well. After 5 days, the virus plaques formed in HeLa cells were counted by crystal violet staining. The activities of various

compounds and acyclovir for inhibition of plaque formation were calculated.

3.4.3. Lymphoproliferation test

The lymphoproliferation test was modified from previously described.^{15,16} The density of PBMC was adjusted to 2×10^6 cells/ml before use. 100 μ l of cell suspension was applied into each well of a 96-well flat-bottomed plate (Nunc 167008, Nunclon, Raskilde, Denmark) with or without PHA (Sigma). Various compounds were added to the cells at 100 μ M. The plates were incubated in 5 % CO₂-air humidified atmosphere at 37 °C for 3 days. Subsequently, tritiated thymidine (1 μ Ci/well, NEN) was added into each well. After a 16 hr incubation, the cells were harvested on glass fiber filters by an automatic harvester (Dynatech, Multimash 2000, Billingshurst, U.K.). Radioactivity in the filters was measured by a scintillation counting. IL-2 (interleukin 2) and cyclosporine A were used as positive and negative standard compounds, respectively.

Acknowledgement

The authors are grateful to the National Science Council, Taipei, Taiwan, for financial support (Grant # NSC 95-2323-B-002-018).

References and notes

1. Fabricius, K. and Alderslade, P., *Soft Corals and Sea Fans*; Australian Institute of Marine Science, Townsville MC, 2001, p.146.
2. Burns, K. P., Kazlauskas, R., Murphy, P. T., Wells, R. J. and Schönholzer, P., *Aust. J. Chem.* **1982**, *35*, 85.
3. Bowden, B. F., Coll, J. C. and Tapiolas, D. M., *Aust. J. Chem.* **1983**, *36*, 211.
4. Bowden, B. F., Coll, J. C., Gulbis, J. M., Mackay, M. F. and Willis, R. H., *Aust. J. Chem.*, **1986**, *39*, 803.

5. Konig, G. M. and Wright, A. D., *J. Nat. Prod.* **1993**, *56*, 2198.
6. Herazi, M. and Croteau, R. *Planta Med.* **1997**, *63*, 291.
7. Duh, C. Y., El-Gamal, A. A. H, Wang, S. K. and Dai, C. F., *J. Nat. Prod.* **2002**, *65*, 1429.
8. Shen, Y. C., Ho, C. J., Kuo, Y. H. and Lin, Y. S., *Bioorg. Med. Chem. Lett.* **2006**, *16*, 2369.
9. Duh, C. Y., Li, C. H., Wang, S. K. and Dai, C. F., *J. Nat. Prod.* **2006**, *69*, 1188.
10. Parmar, V. S., Jha, A., Bisht, K. S., Taneja, P., Singh, S. K., Kumar, A., Jain, R. and Olsen, C. E. *Phytochemistry* **1999**, *50*, 1267.
11. Shen, Y. C., Lin, J. J., Wu, Y. R., Chang, J. Y., Duh, C. Y. and Lo, K. L., *Tetrahedron lett.* **2006**, *47*, 6651.
12. Shen, Y. C., Lin, Y. S., Kuo, Y. H. and Cheng, Y. B., *Tetrahedron letter* **2005**, *46*, 7893.
13. Ohtani, I, Kusumi, T., Kashman, Y. and Kakisawa, H., *J. Am. Chem. Soc.* **1991**, *113*, 4092.
14. Kuo, Y. C., Lin, L. C., Tsai, W. J., Chou, C. J., Kung, S. H., Ho, Y. H., *Antimicrob. Agents* **2002**, *46*, 2854.
15. Kuo, Y. C., Yang, N. S., Chou, C. J., Lin, L. C., Tsai, W. J., *Molecular Pharmacology* **2000**, *58*, 1057.
16. Kuo, Y. C., Lu, C. K., Huang, L. W., Kuo, Y. H., Chang, C., Hsu, F. L., Lee, T. H., *Planta Med.* **2005**, *71*, 421.




Figure 1. Key NOESY correlations of **4**.




Figure 2. Key NOESY correlations of **6**.

Table 1. ^1H NMR data (CDCl_3 , 300MHz) for compounds **1-8** (δ in ppm, J in Hz).^a

position	1	2	3	4	5	6	7	8
1	1.75 m	1.62 m	1.45 m	1.51 m	1.51 m	1.68 m	1.48 m	1.55 m
2	1.73 m	1.20 m	1.43 m	2.32 m	2.28 m	2.28 m	1.81 m	2.16 m
	(2H)	(2H)	(2H)	(2H)	(2H)	1.81 m	1.26 m	1.74 m
3	1.98 m	1.49 m	2.19 m	2.25 m	2.20 m	2.30 m	2.01 m	2.38 m
	(2H)	1.25 m	1.09 m	(2H)	2.08 m	1.96 m	1.76 m	2.11 m
5	2.51 m	3.15 d	2.65 m	2.61 m	2.66 m	2.57 dd	2.02 m	2.51 d
	2.11 m	(13)	2.21 m	2.20 m	2.25 m	(4.4, 4.2)	1.76 m	(11.4)
		2.97d(13)				1.86 m		2.36 m
6	3.67 m		4.49 m	4.51 m	4.50 t	5.54 m	2.17 m	4.36 t
					(8.5)		(2H)	(8.1)
7	2.41 m	6.40 s	5.46 d	5.49 d	5.46 d	5.03 d	2.82 d	5.54 d
	2.29 m		(8.7)	(7.5)	(8.4)	(9.9)	(9.0)	(7.8)
9	5.72 s	3.24 d	3.06 d	3.08 d	3.08 d	3.38 d	2.41 d	3.50 d
		(11.9)	(14.4)	(14.6)	(14.6)	(5.6)	(12.0)	(18.0)
		2.96 d	2.53 d	2.56 d	2.53 d		2.06 m	3.13 d
		(11.9)	(14.4)	(14.6)	(14.6)			(18.0)
10							4.58d	
							(12)	
12	4.98 dd							
	(8.6,5.8)							
13	2.50 m	1.51 m	2.10 m	1.85 m	1.70 m	2.23 m	2.28 d	2.39 m
	2.35 m	(2H)	1.64 m	1.59 m	1.55 m	2.07 m	(10.2)	(2H)
							2.10 m	
14	1.49 m	2.25 m	1.08 m	1.12 m	1.88 m	2.06 m	2.00 m	1.64 m
	(2H)	1.20 m	(2H)	(2H)	(2H)	1.64 m	(2H)	1.50 m
16	1.32 s	1.58 s	0.95 s	1.33 s	1.32 s	1.40 s	1.09 s	1.21 s
17	1.12 s	1.31 s	1.32 s	0.98 s	0.97 s	1.16 s	1.18 s	1.24 s
18	4.89 s	4.94 s	4.92 s	4.95 s	4.93 s	4.89 s	4.73 s	4.87 s
	(2H)	4.85 s	(2H)	(2H)	(2H)	4.84 s	4.67 s	4.84 s
19	2.07 s	2.01 s	1.81 s	1.83 s	1.81 s	1.75 s	1.36 s	1.62 s
20			4.70 s	5.86 s	5.62 s	6.01d(5.6)	1.85	
							s	
21								4.17 q
								(7.2)
22				6.18 m				1.28 t
								(7.2)
23				5.93 d				
				(10)				
				6.51 d				
				(15.7)				

6-Ac	2.01 s
20-Ac	2.11 s 2.12 s

^aAssignments were made by COSY, HMQC and HMBC techniques.

Table 2. ^{13}C NMR data (CDCl_3 , 75 MHz) for compounds **1-8**.^a

C	1	2	3	4	5	6	7	8
1	43.3 d	44.2 d	44.3 d	44.2 d	44.1 d	41.7 d	42.6 d	42.3 d
2	29.2 t	17.2 t	25.8 t	26.1 t	25.4 t	22.2 t	27.0 t	24.4 t
3	32.0 t	33.8 t	37.7 t	37.8 t	37.8 t	30.7 t	31.9 t	33.8 t
4	146.1 s	143.7 s	145.6 s	145.9 s	145.8	144.7	151.2	146.7
					s	s	s	s
5	43.6 t	54.4 t	45.8 t	45.9 t	45.9 t	42.5 t	29.7 t	44.1 t
6	70.1 d	199.0 s	69.2 d	69.3 d	69.3 d	69.9 d	30.3 t	69.7 d
7	46.4 t	129.8 d	133.6 d	133.8 d	133.6	127.8	65.2 d	136.9
					d	d		d
8	151.2 s	150.3 s	131.8 s	132.5 s	132.5	134.9	59.5 s	130.9
					s	s		s
9	119.7 d	49.2 t	41.2 t	40.7 t	40.8 t	60.8 d	47.9 t	54.9 t
10	166.5 s	108.2 s	94.7 s	94.7 s	94.7 s	202.6	67.1	207.4
						s	d	s
11	210.6 s	167.2 s	74.3 s	75.1 s	72.5 s	147.9	140.2	160.7
						s	s	s
12	76.8 d	129.1 s	78.2 s	78.8 s	79.7 s	165.7	133.9	124.9
						s	s	s
13	26.1 t	36.0 t	30.9 t	30.7 t	26.3 t	22.7 t	33.8 t	21.6 t
14	19.0 t	24.9 t	33.9 t	33.9 t	33.9 t	28.5 t	31.8 t	32.9 t
15	49.4 s	38.5 s	37.5 s	37.5 s	37.7 s	33.9 s	37.1 s	38.9 s
16	28.1 q	34.2 q	24.9 q	26.1 q	26.4 q	23.9 q	24.9 q	25.4 q
17	22.9 q	24.6 q	26.1 q	25.1 q	25.2 q	30.7 q	33.4 q	33.5 q
18	114.2 t	115.9 t	115.7 t	116.0 t	115.8 t	112.8 t	109.6 t	114.7 t
19	20.3 q	19.2 q	17.2 q	17.5 q	17.3 q	18.9 q	17.2 q	18.5 q
20		170.1 s	98.8 d	96.6 d	100.9	74.2 d	21.7 q	166.9
					s			s
21				164.8 s				61.2 t
22				127.8 d				14.1 q
23				132.5 t				
6-Ac						170.5		
						s		
						21.4 q		
20-Ac					170.1	170.5		
					s	s		
					20.9 q	21.1 q		

^aAssignments were aided by DEPT, HMQC and HMBC experiments

Table 3. Inhibition of HSV-1 replication by compounds **1-8**.^a

Compound (100 μ M)	Inhibitory activity (%)
1	18.5
2	5.2
3	19.4
4	6.6
5	13.7
6	21.8
7	10.0
8	22.3

^a HSV-1: Herpes simplex virus type 1

Table 4. Effects of compounds **1-8** on PBMC proliferation induced by PHA

Compound (100 µg/ml)	Activity (%)	
	Resting ^a	PHA (5 µg/ml)
1	-61.9±4.5	89.4±2.4
2	7.0±1.0	-8.6±0.3
3	37.8±8.9	26.7±0.2
4	-37.8±2.6	-2.6±4.0
5	4.3±4.6	-27.8±6.5
6	31.6±8.9	2.9±0.1
7	45.7±8.5	162.6±63.7
8	11.5±1.1	-84.2±1.5
IL-2 (10 U/ml)	95.3±10.1	208±25.7
Cyclosporine A (2.5 µg/ml)	-15.9±4.4	-92.2±6.8

^a “-“ represents inhibitory activity; positive represents enhancement
※ of proliferation.

成果自評：

本計畫執行很順利，成果豐碩。